Epidiolex

Product data

Locally preserved regulatory fields

Active ingredients

CANNABIDIOL, epidiolex

Route

ORAL

Dosage form

SOLUTION

Marketing holder

Jazz Pharmaceuticals, Inc.

Catalog status

FDA approved

Source-reported status

FDA approved

Linked local records

Related local records

Substance links use source-reported active ingredients. Condition links come from registered study context and are not efficacy claims.

Source-reported use

Indications in regulatory records

1 INDICATIONS AND USAGE EPIDIOLEX is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC) in patients 1 year of age and older. EPIDIOLEX is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in patients 1 year of age and older ( 1 )

Medicine identity matching

RxNorm candidates

RxNorm normalizes identity; FAERS supplies non-causal post-market signals.

Safety signals

Locally preserved FAERS reports

FAERS/AEMS reports are post-market signals. Counts do not establish causality or incidence and may contain duplicates or reporting bias.